Australian clinical-stage company Immutep has announced positive data from the INSIGHT-003 trial evaluating its eftilagimod alpha in combination with MSD's KEYTRUDA (pembrolizumab) and chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer. …
Australian company says 'Efti' INSIGHT-003 lung cancer trial reveals positive survival data
November 14, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Genomic testing to reach more patients with hard to treat cancers
September 17, 2026 - - Latest News -
Eight women named finalists for 2026 Marie Krogh Young Women in Science Prize
September 17, 2026 - - Latest News -
'Your success makes you a target and take it as a compliment'
September 16, 2026 - - Latest News -
New Zealand ranks last among wealthy nations on modern medicines access, new report finds
September 16, 2026 - - Latest News -
Young Australians badly misjudge when fertility starts to decline, new survey finds
September 16, 2026 - - Latest News -
New research points to a 'Doctor gap' holding back clinical trial participation in Australia
September 16, 2026 - - Latest News -
From constitutional promise to creaking system - the PBS at 80
September 16, 2026 - - Latest News